US weight-loss biotech’s $600mn fund raise signals China’s role in drug trials
Clinical studies can be finished faster and cheaper than in US and provide an earlier sign of a drug’s potential
Related reading
Why investors are chasing US biotechs with Chinese characteristics
Drugs developed in Asian nation are increasingly being used to seed US start-ups
Chinese drugmakers shift from copycats to global innovators
Reforms, faster development and lower costs have turbocharged growth
AstraZeneca strikes $4.7bn China deal to boost weight-loss drugs pipeline
Drugmaker expands push into fast-growing market
UK biotech keeps selling itself to America
A shortage of late-stage capital pushes the biggest prizes into US hands
The race to launch a pill for weight loss
Despite success with injectable drugs pharma companies are investing heavily in tablets, long considered the holy grail of…
Europe’s pharma industry risks lagging behind US and China, says German…
Boehringer Ingelheim says pricing regime hinders access to treatments as group touts liver benefits from weight-loss drug